The authors further demonstrated that inhibiting or depleting CDK5 increases the level of FBXO22 with a concomitant decrease in PD-L1, leading to increased sensitivity of NSCLC cells to DNA damage (Fig. 6B). This evidence concerns the gene CDK5 and non-small cell lung carcinoma.